GenSight Biologics S.A.
SIGHT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €48 | €897 | €1,728 | €1,450 |
| % Growth | -94.6% | -48.1% | 19.2% | – |
| Cost of Goods Sold | €0 | €0 | €0 | -€1,925 |
| Gross Profit | €48 | €897 | €1,728 | €1,642 |
| % Margin | 100% | 100% | 100% | 113.2% |
| R&D Expenses | €4,285 | €6,080 | €6,288 | €9,110 |
| G&A Expenses | €2,326 | €2,803 | €2,583 | €2,365 |
| SG&A Expenses | €2,553 | €3,228 | €2,843 | €5,480 |
| Sales & Mktg Exp. | €227 | €425 | €260 | €3,115 |
| Other Operating Expenses | €0 | -€1 | €0 | €1 |
| Operating Expenses | €6,838 | €9,307 | €9,131 | €14,591 |
| Operating Income | -€6,790 | -€8,410 | -€7,403 | -€11,437 |
| % Margin | -14,145.8% | -937.6% | -428.4% | -788.8% |
| Other Income/Exp. Net | -€186 | €273 | €1,560 | -€1,657 |
| Pre-Tax Income | -€6,976 | -€8,137 | -€5,843 | -€13,095 |
| Tax Expense | €9 | €16 | €5 | €1,163 |
| Net Income | -€6,967 | -€8,153 | -€5,848 | -€14,258 |
| % Margin | -14,514.6% | -908.9% | -338.4% | -983.3% |
| EPS | -0.054 | -0.075 | -0.071 | -0.28 |
| % Growth | 27.5% | -5.9% | 74.8% | – |
| EPS Diluted | -0.054 | -0.075 | -0.071 | -0.28 |
| Weighted Avg Shares Out | 128,273 | 108,852 | 82,749 | 50,559 |
| Weighted Avg Shares Out Dil | 128,272 | 108,851 | 82,749 | 50,559 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €2,168 | €621 | €466 | €1,810 |
| Depreciation & Amortization | €80 | €998 | €61 | €1,097 |
| EBITDA | -€6,710 | -€7,413 | -€7,342 | -€11,505 |
| % Margin | -13,979.2% | -826.4% | -424.9% | -793.4% |